Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
Masanori AtsukawaHaruki UojimaHidenori ToyodaAtsushi HiraokaYoshitake AraseMasanori AtsukawaNorio ItokawaTomomi OkuboToshifumi TadaKazushi NumataManabu MorimotoMakoto SugimoriAkito NozakiShuichiro IwasakiSatoshi YasudaYuichi KoshiyamaYusuke MishimaKota TsuruyaChikako TokoroYuki MiuraHisashi HidakaTakashi KumadaChika KusanoTatehiro KagawaShin MaedaPublished in: Hepatology international (2024)
Although, as far as we examined, no ctDNA mutations in blood were found to be related to ATZ + BV treatment efficacy, serum CXCL9 and LAG-3 levels, which are related to the cancer-immune cycle, were associated with treatment efficacy and could be predictive markers of the efficacy of ATZ + BV treatment in HCC patients.